• Sachet: 1-3 years old children
• Lozenge: >3 years old children and teenagers

People with immunosuppression. Bactoblis® should not be taken by consumers with contraindications including iatrogenic immunosuppression, hypersensitivity, others. In case of any doubt, we recommend asking a healthcare professional.

We recommend not to eat or drink anything when taking Bactoblis®, at least 2 hours. Preferably before going to sleep.

No. In the case of the lozenge, it needs to be slowly dissolved in the mouth, and in the case of the sachet, we need to use a clean finger or pacifier for application; this will guarantee effective oral colonization.

We have developed a powder sachet formula specifically for children under three years of age with all the Bactoblis® benefits. However, if the sachet formula is not a good alternative from your side, crushing the lozenge can be an option, considering that the lozenge contains living bacteria of Streptococcus salivarius K12, and by doing this, we may alter them.

Human. Streptococcus salivarius is of human origin, isolated from a healthy child

No. Even though Streptococcus salivarius have demonstrated several benefits for other disorders such as Halitosis, Gingivitis, Caries, others; we do not allow promoting these benefits in association with Bactoblis®.

No. Bactoblis® contains Streptococcus salivarius K12, a good bacteria naturally present in the oral cavity, and is immune to its salivaricin, so it protects itself from its weapons. The salivaricin substances only attack bad bacteria, such as Streptococcus pyogenes, Streptococcus mutans, Streptococcus mites, and other harmful Streptococci species.

No. Fructose content is too low to have an impact on caries development. Bactoblis® lozenge contains 635 mg of total sugars, and the health recommendation is 25 g per day; it represents only 2% of the recommended amount. In fact, Bactoblis® have demonstrated to effectively inhibit Strepcoccus mutans (the responsible bacteria for caries development).

No. Fructose content is too low to have an impact on caries development. Bactoblis® lozenge contains 635 mg of total sugars, and the health recommendation is 25 g per day; it represents only 2% of the recommended amount. In fact, Bactoblis® have demonstrated to effectively inhibit Strepcoccus mutans (the responsible bacteria for caries development).

The primary mechanism behind Bactoblis® is inhibiting pathogens in respiratory infections. However, the literature on risk factors for recurrent respiratory infections identified allergies as a risk factor. Given that, one who suffers from allergies is more likely to develop respiratory infections and subsequently is more likely to be in the target group for Bactoblis®. The underlying mechanism of probiotic products (e.g., Rhinozyn®, Bluestone Pharma) is balancing/shifting the immune system.

The likelihood that Streptococcus salivarius K12 reaches the gastrointestinal tract is very low. Usually, K12 does not survive the passage through the stomach due to the low pH (1,5-2 pH) after the meals, it is exceptionally high, and we recommend taking Bactoblis® after meals. Moreover, the prevalence of Crohn’s colitis is 0,5 % in Germany, meaning it is a sporadic disease. Some sporadic cases might occur where they found Streptococcus salivarius in the gastrointestinal tract associated with SIBO (we found one paper identifying one patient). However, the role Streptococcus salivarius plays in this regard is unknown. Considering the pH of the stomach and the low prevalence of the diseases mentioned above, the topic should play a minor role in praxis. However, if a patient is immunosuppressed (due to medication, chemotherapy, etc.) or has concerns about such rare cases, we always recommend consulting with a healthcare professional.

Yes. Bactoblis® is certified as Kosher and does not contain any animal substances.

No, but it may contain residues of Milk. In Bactoblis®, the only source of Lactose is Streptococcus salivarius K12 lyophilisate. S. salivarius belongs to the lactic acid bacteria, and the sugar fermentation profile indicates S. salivarius K12 metabolizes Lactose during this process. According to the EFSA panel’s scientific opinion on Lactose thresholds in Lactose intolerance and galactosemia (EFSA Journal 2010), the majority of subjects with Lactose maldigestion will tolerate up to 12 g of Lactose as a single dose with no or minor symptoms. A Bactoblis® single dose, can contain 1.95 mg if no lactose is metabolized during fermentation.

Vegetarian. Due to the minor content of lactose, Bactoblis® is not 100% vegan.

Yes. The product does not contain any cereals containing gluten.

Bulking agent. Has carrier properties for probiotics. It is a safe a well-recognized food ingredient in the pharmaceutical and food supplement industry.

No. It is recognized as generally safe for children.

Usually, the variation in the treatment group is higher. For some patients, the medication has higher effects; for others lower; while the variation (or standard deviation) in the placebo group is comparably low because the placebo effects have not such high variations. In several cases, the budget is the limiting factor in clinical trials. Due to budget constraints, one often chooses to “add” more patients in the treatment group (in this case, Bactoblis®) to get significant and robust study findings. If no significant differences between the two groups can be identified, everything works well.